Post by Cyclo Therapeutics, A Rafael Company

Reaching the conclusion of the pivotal Phase 3 TransportNPC™ trial for Niemann Pick Disease Type C is a monumental achievement that belongs, first and foremost, to the patients and families, advocacy organizations, and physicians who stood at the heart of this global effort. Thank you for your commitment to advancing our understanding of this rare and underserved disease! https://lnkd.in/eMtWbwiQ